My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

8.470 +0.250 (+3.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Recap: Seres Therapeutics Q2 Earnings ↗

August 03, 2022

Seres Therapeutics (NASDAQ:MCRB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Preview: Seres Therapeutics ↗

August 02, 2022

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Seres...

Via Benzinga

Why Is Pinterest Higher By 14%? 20 Stocks Moving In Friday's Pre-Market Session ↗

July 15, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) rose 55% to $3.41 in pre-market trading. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on...

Via Benzinga

Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments ↗

July 14, 2022

Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and...

Via Benzinga

More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying ↗

July 08, 2022

U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug ↗

June 07, 2022

Via Benzinga

Recap: Seres Therapeutics Q1 Earnings ↗

May 04, 2022

Seres Therapeutics (NASDAQ:MCRB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 22, 2022

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 07, 2022

Via Benzinga

Seres Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 19, 2022

Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter.

Via Benzinga

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis ↗

April 07, 2022

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

79 Biggest Movers From Yesterday ↗

June 08, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Preview: Seres Therapeutics's Earnings ↗

May 03, 2022

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Seres...

Via Benzinga

How To Attend Seres Therapeutics Q1 2022 Earnings Conference Call ↗

April 29, 2022

Seres Therapeutics (NASDAQ:MCRB) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 20, 2022

Gainers

Via Benzinga

Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study ↗

March 18, 2022

Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting.

Via Benzinga

Seres Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 08, 2022

Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a...

Via Benzinga

Seres Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Seres Therapeutics (NASDAQ:MCRB) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Earnings Preview: Seres Therapeutics ↗

February 28, 2022

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection ↗

January 20, 2022

Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (...

Via Benzinga

Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study ↗

December 16, 2021

Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate...

Via Benzinga

Jim Cramer Shares His Thoughts On Novavax, ViacomCBS And More ↗

December 06, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Seres Therapeutics, Inc. (NASDAQ:

Via Benzinga

Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday ↗

November 30, 2021

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

Via The Motley Fool

Topics Stocks

52 Biggest Movers From Yesterday ↗

December 01, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...

Via Benzinga

35 Stocks Moving In Tuesday's Mid-Day Session ↗

November 30, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...

Via Benzinga

Looking Into Seres Therapeutics's Return On Capital Employed ↗

November 11, 2021

According to Benzinga Pro, during Q3, Seres Therapeutics (NASDAQ:MCRB) earned $68.41 million, a 242.09% increase from the preceding quarter. Seres Therapeutics also posted a total...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.